Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality

Journal of Dermatological Treatment

Volumn 22, Issue 4, 2011, Pages 229-232

  Lernia, Vito Di ^a   Ricci, Cinzia ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Anti TNF; Ciclosporin; Infliximab; Psoriasis; PUVA; Skin cancer

Indexed keywords

CYCLOSPORIN A; EFALIZUMAB; ETRETIN; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; OLMESARTAN; PSORALEN; QUINAPRIL;

ACTINIC KERATOSIS; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXCISION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KERATOACANTHOMA; LIPID BLOOD LEVEL; MALE; MULTIPLE CANCER; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PUVA; REMISSION; SIDE EFFECT; SKIN BIOPSY; SKIN CARCINOMA; SKIN FRAGILITY; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET A RADIATION;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; PSORIASIS; PUVA THERAPY; SKIN NEOPLASMS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960465829     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546631003681086     Document Type: Article

References (15)

1. Patel RV, Clark LN, Lebowl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60:1001-1017.
2. Stern RS, Leibman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst. 1998;90:1278-1284. (Pubitemid 28433472)
3. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow up Study. Cancer. 1994;73:2759-2764. (Pubitemid 24166263)
4. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: Nested cohort cross-over study. Lancet. 2001;358:1042-1045. (Pubitemid 32925124)
5. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol. 2003;120:211-216. (Pubitemid 36513069)
6. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, et al. A review of malignancies during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213:204-214. (Pubitemid 44567830)
7. Chakravarty EF, MIchaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130-2135. (Pubitemid 41587856)
8. Sheppard J, Raza K, Buckley CD. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology. 2007;46:1623-1624.
9. Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol. 2004;50:S75-S77. (Pubitemid 38580526)
10. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45:953-956. (Pubitemid 33096643)
11. Fryrear RS 2nd, Wiggins AK, Sangueza O, Yosipovitch G. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol. 2004;51:1026. (Pubitemid 39593030)
12. Williams GM. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur J Cancer Prev. 2008;17: 169-177. (Pubitemid 351301629)
13. Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, et al. An anti-tumor necrosis factor-alfa antibody inhibits the development of experimental skin tumors. Mol Cancer Ther. 2003;2:445-451.
14. National Institute for Clinical Excellence (NICE) Guidelines, TA104 Psoriatic arthritis, etanercept and infliximab-guidance, July 2006; and NICE Guidelines, TA103 Psoriasis, efalizumab and etanercept-guidance, July 2006.
15. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(suppl 2):1-70.